文献速递基础与转化研究新药、器械与细胞基因治疗研发

反义疗法在大鼠亚历山大病模型中逆转GFAP病理、白质缺陷和运动障碍

Antisense therapy in a rat model of Alexander disease reverses GFAP pathology, white matter deficits, and motor impairment.
PubMed 文献 · Sci Transl Med · 2021-11-17

亚历山大病(AxD)由GFAP功能获得性突变引起,目前仅对症支持治疗。研究建立具有Rosenthal纤维、广泛星形胶质细胞增生和白质缺陷的大鼠AxD模型,单次Gfap靶向反义寡核苷酸(ASO)治疗可持久抑制GFAP、逆转病理,并根据治疗年龄预防或减轻白质缺陷和运动障碍。

要点

  • 新型大鼠AxD模型再现GFAP聚集、星形胶质细胞增生和白质缺陷等人类疾病特征。
  • 单次Gfap靶向ASO治疗可持久抑制GFAP并逆转病理。
  • 根据治疗年龄,ASO可预防或减轻白质缺陷和运动障碍。

核心结论

  • 在大鼠AxD模型中,单次Gfap靶向ASO治疗可持久抑制GFAP、逆转GFAP病理,并根据治疗年龄预防或减轻白质缺陷和运动障碍,提示ASO疗法有潜力预防并逆转疾病多方面表现。

研究设计与样本

  • 研究采用大鼠AxD模型,该模型在出生后前几周发育正常,断奶后生长迟缓,成熟后出现严重运动障碍,约14%在6至12周龄间不明原因死亡。

主要发现

  • 大鼠AxD模型表现出GFAP聚集形成的Rosenthal纤维、广泛星形胶质细胞增生和白质缺陷等标志性病理。
  • 单次Gfap靶向ASO治疗提供持久抑制,逆转GFAP病理。
  • 根据治疗年龄,ASO预防或减轻白质缺陷和运动障碍。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Alexander disease (AxD) is a devastating leukodystrophy caused by gain-of-function mutations in GFAP, and the only available treatments are supportive. Recent advances in antisense oligonucleotide (ASO) therapy have demonstrated that transcript targeting can be a successful strategy for human neurodegenerative diseases amenable to this approach. We have previously used mouse models of AxD to show that Gfap-targeted ASO suppresses protein accumulation and reverses pathology; however, the mice have a mild phenotype with no apparent leukodystrophy or overt clinical features and are therefore limited for assessing functional outcomes. In this report, we introduce a rat model of AxD that exhibits hallmark pathology with GFAP aggregation in the form of Rosenthal fibers, widespread astrogliosis, and white matter deficits. These animals develop normally during the first postnatal weeks but fail to thrive after weaning and develop severe motor deficits as they mature, with about 14% dying of unknown cause between 6 and 12 weeks of age. In this model, a single treatment with Gfap-targeted ASO provides long-lasting suppression, reverses GFAP pathology, and, depending on age of treatment, prevents or mitigates white matter deficits and motor impairment. In this report, we characterize an improved animal model of AxD with myelin pathology and motor impairment, recapitulating prominent features of the human disease, and use this model to show that ASO therapy has the potential to not only prevent but also reverse many aspects of disease.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Hagemann TL, Powers B, Lin NH, et al. Antisense therapy in a rat model of Alexander disease reverses GFAP pathology, white matter deficits, and motor impairment. Sci Transl Med. 2021. PMID: 34788075. doi:10.1126/scitranslmed.abg4711

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。